Alnylam Pharmaceuticals, Inc. (ALNY)
296.27
+0.36
(+0.12%)
USD |
NASDAQ |
May 08, 12:59
Alnylam Pharmaceuticals Cash from Investing (Quarterly) : -25.54M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -3.916B |
| Pfizer Inc. | 785.00M |
| Aldeyra Therapeutics, Inc. | 16.00M |
| Ionis Pharmaceuticals, Inc. | 536.82M |
| Glaukos Corp. | 10.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 70.50M |
| Cash from Financing (Quarterly) | 15.71M |
| Free Cash Flow | 641.34M |
| Free Cash Flow Per Share (Quarterly) | 0.3521 |
| Free Cash Flow to Equity (Quarterly) | 47.24M |
| Free Cash Flow to Firm (Quarterly) | 113.06M |
| Free Cash Flow Yield | 1.60% |